A Systematic Review on the Efficacy and Safety of Chloroquine for the Treatment of COVID-19
Cortegiani et al.
, A Systematic Review on the Efficacy and Safety of Chloroquine for the Treatment of COVID-19
, J. Crit. Care, June 2020, 57:279-283, doi:10.1016/j.jcrc.2020.03.005, Epub Mar 10, 2020 (meta analysis)
Review of six articles and 23 ongoing clinical trials in China recommending research and clinical use adhering to MEURI.
Currently there are 36 HCQ early treatment studies
and meta analysis shows:
Cortegiani et al., 10 Mar 2020, peer-reviewed, 5 authors.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
Journal of Critical Care 57 (2020) 279–283
Contents lists available at ScienceDirect
Journal of Critical Care
journal homepage: www.journals.elsevier.com/journal-of-critical-care
A systematic review on the efﬁcacy and safety of chloroquine
for the treatment of COVID-19
Andrea Cortegiani a,⁎, Giulia Ingoglia a, Mariachiara Ippolito a, Antonino Giarratano a, Sharon Einav b
Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Italy
Intensive Care Unit of the Shaare Zedek Medical Medical Centre, Hebrew University Faculty of Medicine, Jerusalem, Israel
a r t i c l e
i n f o
a b s t r a c t
Purpose: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this
time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting
the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19.
Methods: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19.
Results: We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper,
two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in
limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro.
Conclusions: There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI)
framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data
from high-quality clinical trials are urgently needed.
© 2020 Elsevier Inc. All rights reserved.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.